A Phase 2 study of combination therapy with arsenic trioxide and gemtuzumab ozogamicin in patients with myelodysplastic syndromes or secondary acute myeloid leukemia
Overview of attention for article published in Cancer (0008543X), October 2010
Altmetric Badge
About this Attention Score
-
In the top 25% of all research outputs scored by Altmetric
-
High Attention Score compared to outputs of the same age (81st percentile)
-
Good Attention Score compared to outputs of the same age and source (65th percentile)
Readers on
- mendeley
- 42 Mendeley